Navigation Links
Endo Health Solutions Announces Receipt of Requisite Consents and Expiration of Consent Solicitations Relating to its 7% Senior Notes Due 2019, 7.00% Senior Notes Due 2020 and 7 1/4% Senior Notes Due 2022
Date:11/27/2013

MALVERN, Pa., Nov. 27, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) ("Endo") today announced that, as reported by the tabulation agent, the requisite holders of its senior notes listed below (collectively the "Notes") had consented to the proposed amendments to the indentures governing the Notes (the "Proposed Amendments"), upon the terms and subject to the conditions set forth in the Consent Solicitation Statement, dated November 19, 2013 (the "Statement").

 Series of NotesCUSIPOutstanding Principal AmountConsents ReceivedPercentage7% Senior Notes due 201929264F AG1

$500,000,000

$485,445,000

97.1%7.00% Senior Notes due 202029264F AE6

$400,000,000

$393,065,000

98.3%7¼% Senior Notes due 202229264F AJ5

$400,000,000

$398,145,000

99.5% 

As of 5:00 P.M., New York City time, on November 27, 2013 (the "Expiration Date"), Endo received valid consents in respect of a majority in aggregate principal amount of each series of the outstanding Notes. Accordingly, Endo intends to enter into supplemental indentures, by and among Endo, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, to each of the indentures governing the Notes, reflecting the Proposed Amendments. Subject to the terms and conditions set forth in the Statement, Endo will pay eligible holders who have validly delivered and not revoked consents on or prior to the Expiration Date, a cash payment equal to $2.50 per $1,000 aggregate principal amount of each series of Notes consented (the "Consent Fee").

The Consent Fee will be payable subject to satisfaction or, where possible, waiver of, the Consent Conditions (as defined in the Statement), including the closing of the Transactions (as defined in the Statement). The Propos
'/>"/>

SOURCE Endo Health Solutions Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
2. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. BD to Present at the 25th Annual Piper Jaffray Healthcare Conference
4. TCS Named a Global Leader in IDC MarketScape: Worldwide Life Science Sales & Marketing ITO 2013 Vendor Assessment by IDC Health Insights
5. CVS Caremark to Purchase Coram Infusion Business from Apria Healthcare, Expanding Specialty Pharmacy Offering
6. New Agreements and Stock Movements in Healthcare Companies - Research Report on Abbott, Thermo Fisher, Intuitive Surgical, Mindray, and Zeltiq
7. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
8. Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
9. RXi Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference
10. Quest Diagnostics To Speak At The Piper Jaffray 25th Annual Healthcare Conference
11. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... in the upcoming Rodman & Renshaw 17 th ... in New York City .  Dr. ... a corporate overview on September 9, 2015. ...
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... Sep. 04, 2015 ... the addition of the "Pharmacovigilance (London, UK ... offering. Understanding PhV today - the ... working in Drug safety. This course ... with pharmacovigilance. New entrants as well as experienced ...
Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2
... N.J., March 17 Hereditary angioedema (HAE) is ... States each year. Patients with HAE suffer from ... skin, airway, and visceral organs. Left untreated, most ... per month. Chronic therapy with attenuated androgens or ...
... Surgeons to Lead Pivotal TrialANN ARBOR, Mich., March 17 ... appointed David Seth Feldman, MD/PhD, FACC, FAHA to be ... United States, studying the new, third generation DuraHeart(TM) Left ... Francis Pagani, Director of the Heart Transplant and Center ...
Cached Medicine Technology:Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3
(Date:9/4/2015)... , ... September 04, 2015 , ... According to an ... developed that changes color when subjected to an impact force that is great enough ... implemented in helmets or other sporting equipment so that coaches or officials would instantly ...
(Date:9/4/2015)... ... ... The Schmidt National Law Group filed an Essure® lawsuit against Bayer and ... Group, a leading firm in mass-tort litigation, has filed a lawsuit in the federal ... other Bayer affiliates for injuries alleged to have been caused by her Essure® contraceptive ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Products Association (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements ... handling rules constantly evolving in the consumer goods industry, it can be difficult ...
(Date:9/4/2015)... Maui HI (PRWEB) , ... September 04, 2015 , ... ... the best ways for couples to explore, revitalize and strengthen their ‘couple-ness,’” says ... and his team at Four Seasons Resort Maui, the island’s only Forbes Five Star ...
(Date:9/4/2015)... Portland, ME (PRWEB) , ... September 04, 2015 ... ... Symposium focus on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 ... ihsymposium.com/focus-event. , Speakers at the 2015 symposium are doctors and researchers at the ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... BASEL, Switzerland, Feb. 19 Roche (SWX:,ROG.VX; ... (Nasdaq: VMSI ),today announced that Roche has ... Ventana. As of the expiration of the subsequent,offering ... had purchased a total of approximately 34,545,323 shares ...
... that uses millions of identical antibodies to boost the ... patients whose tumors recede in response to the treatment ... and rashes. In a new study, a team ... periodic infusions of such "monoclonal" antibodies to patients who ...
... shows , , MONDAY, Feb. 18 (HealthDay News) -- Statins ... to lower cholesterol levels may also cut the risk ... odds of a stroke, French researchers report. , An ... participants showed that those patients who received statins had ...
... Organizations Develop Action Plan, Announce Feline Life-Stage Guidelines ... ... Western Veterinary Conference -- The,American Association of Feline Practitioners (AAFP) today ... in Palm,Springs, Calif., with initial underwriting from Pfizer Animal Health.,Attendees were led ...
... them to kids to try to prevent fluid buildup, analysis ... significantly reduce fluid buildup in young children with inner ear ... in this regard has been a matter of conjecture, with ... and under. So, Dutch researchers did a meta-analysis of several ...
... year ago today, the,American people first learned about ... treating wounded soldiers returning,from Iraq and Afghanistan. Amid ... saw an opportunity to bolster his presidential,campaign. Days ... on former,Secretary of Defense Don Rumsfeld, saying "the ...
Cached Medicine News:Health News:Roche Completes Tender Offer for Ventana Shares 2Health News:Roche Completes Tender Offer for Ventana Shares 3Health News:Roche Completes Tender Offer for Ventana Shares 4Health News:Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer 2Health News:Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer 3Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 2Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 3Health News:CATalyst Summit Declared a Success: It's All About the Cat! 2Health News:CATalyst Summit Declared a Success: It's All About the Cat! 3Health News:Antibiotics Do Little for Inner Ear Infections 2Health News:Walter Reed Anniversary Exposes More McCain Double Talk 2Health News:Walter Reed Anniversary Exposes More McCain Double Talk 3
The new PERIMOUNT Magna heart valve (bioprosthesis), with its true supra-annular design, offers optimal hemodynamics and flow characteristics for treatment of aortic heart valve disease....
... background in high performance ultrasound design ... of echocardiography. Echocardiography imaging requires superior ... sensitive Doppler performance. The Terason Echo ... Teratech Architecture, delivers a compact imaging ...
... In-office. Information. In real time. The FemExam pH ... elevated vaginal fluid pH (pH >= 4.7) and ... is easy to use and delivers accurate results ... a swab containing unprocessed vaginal fluid across each ...
For the quantitative determination of human MMP-9/NGAL Complex concentrations in cell culture supernates, serum,plasma, urine and saliva....
Medicine Products: